{"nctId":"NCT02770365","briefTitle":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy","startDateStruct":{"date":"2016-05"},"conditions":["Atrophy"],"count":695,"armGroups":[{"label":"Test Product","type":"EXPERIMENTAL","interventionNames":["Drug: estrace cream (Perrigo)"]},{"label":"Reference Product","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: estrace cream (Reference)"]},{"label":"Placebo product","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo cream"]}],"interventions":[{"name":"estrace cream (Perrigo)","otherNames":["Perrigo product"]},{"name":"estrace cream (Reference)","otherNames":["Reference Listed Drug product"]},{"name":"Placebo cream","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* postmenopausal female and otherwise healthy, 30 - 75 years of age.\n* ≤ 5% superficial cells on vaginal smear cytology at Visit 1/Screening.\n* vaginal pH \\> 5.0 at Visit 1/Screening\n* Have at least one self-assessed moderate to severe symptom of Vulvar and Vaginal Atrophy identified by the subject as being the most bothersome\n* For women with an intact uterus, vaginal ultrasonography confirmation at Visit 1/Screening of an inactive endometrial lining with an endometrial thickness less than 4 mm.\n* Systolic blood pressure no greater than 150 mm Hg and diastolic blood pressure no greater than 90 mm Hg at Visit 1/Screening and at Visit 2/Randomization\n\nExclusion Criteria:\n\n* Undiagnosed vaginal bleeding or a history of significant risk factors for endometrial cancer.\n* Known, suspected, or history of cancer of the breast or mammogram indicating any abnormalities or subject has a history of cervical cancer.\n* Vaginal ultrasonography for all women with an intact uterus confirming endometrial thickness of 4mm or more\n* History of hypersensitivity or allergy to estradiol or any of the other study medication ingredients.\n* Known or suspected estrogen-dependent neoplasia.\n* Has deep vein thrombosis, pulmonary embolism or history of these conditions.\n\n  • Subject has active arterial thromboembolic disease (e. g. stroke, myocardial infarction) or history of these conditions.\n* Known acute or chronic hepatic disease or dysfunction","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"30 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Identified as Responders","description":"A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH \\< 5.0 with a change from Visit 1 of at least 0.5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"32.0","spread":null},{"groupId":"OG002","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Most Bothersome Symptom","description":"Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":277},"commonTop":[]}}}